In the pharmaceutical industry, the difference is straightforward from the outset. Co-packing means an external partner packages an existing medicine. Conversely, contract manufacturing begins when that partner actively produces the drug product itself from raw materials or active pharmaceutical ingredients (APIs). Distinguishing between the two is vital, as product ownership, process scope, and batch release responsibilities can sit with different parties. Therefore, teams must define this boundary early.
Many project teams search for the difference between co-packing and contract manufacturing because project scopes can look identical on paper. In practice, the clearest way to differentiate them is by checking three points: who owns and supplies the bulk product, what the external partner actually does, and who holds the authorised release role. Once these points are clarified, the outsourcing model typically becomes evident.
• Co-packing begins after the medicine has been manufactured and supplied for packaging.
• Contract manufacturing begins when the external company formulates the drug product itself.
• Primary packaging can still fall under co-packing if the medicine is already supplied in bulk.
• Batch release responsibility must be formally assigned in writing and does not automatically accompany the title of "co-packer."
• Because a single project can involve multiple parties, handover points should be documented early.
What co-packing versus contract manufacturing means in pharma
The concept of co-packing versus contract manufacturing describes a practical boundary in outsourced pharmaceutical activities. Co-packing, often referred to as contract packing, involves packaging a product that has already been manufactured. Contract manufacturing, on the other hand, begins when an external company produces the medicine itself. If you need more detail on the packaging side, our article on pharmaceutical contract packaging explains that scope further.
A brief definition of co-packing is helpful here. A company supplies a finished or semi-finished product to a packaging partner, who then places it into the agreed-upon packaging. This process can include blisters, wallet packs, cartons, leaflets, labels, and serialisation. Essentially, the medicine already exists before any packaging starts. By contrast, the difference between contract packing and contract manufacturing comes down to one core question: who makes the medicine, and who merely packs it?
This distinction matters because the difference between a co-packer and a co-manufacturer affects ownership, controls, quality records, and release steps. Project teams often confuse physical work with formal responsibility. As a result, they can inadvertently delay approvals, miss critical data handovers, or assign essential tasks too late.
A brief definition of co-packing
Co-packing means the external partner focuses on the packaging rather than manufacturing the drug product. The product typically arrives as tablets, capsules, vials, syringes, or another ready-to-pack form. "Semi-finished" generally means the medicine is fully formulated, but its final packaging configuration is pending. Therefore, the packaging partner can execute the packaging process without acting as the drug product manufacturer.
Where contract manufacturing starts
Contract manufacturing begins when the external company receives raw materials or active ingredients and subsequently formulates the drug product. This is the key distinguishing factor in discussions regarding contract packaging versus contract manufacturing organizations (CMOs). A CMO typically has a broader production role, whereas a packaging partner strictly focuses on pack execution and its related controls.
Why the line matters for scope and accountability
Packaging work and drug production occupy entirely different parts of the supply chain. Consequently, they require different agreements and distinct handover points. A single project might involve a drug product manufacturer, a packaging partner, a component supplier, and a serialisation data provider. Therefore, the exact boundaries should be documented in writing before launch planning progresses too far.
How to assess co-packing versus contract manufacturing by product ownership
Bulk product ownership is one of the fastest ways to place a project on the right side of this line. In a typical co-packing setup, the brand owner or an appointed manufacturer owns and supplies the finished or semi-finished product to the packaging partner. In a standard contract manufacturing arrangement, the external company receives raw materials and manufactures the drug product as part of its agreed scope.
This point is crucial because component supply alone does not answer the underlying question. A customer might supply cartons, labels, leaflets, or blister materials, or the packaging partner might source some or all of these components themselves. Even with these variations, the project remains co-packing if the medicine itself is already made and merely supplied for packaging. Therefore, bulk product ownership is typically the clearest marker.
A simple example helps illustrate this. If a brand owner sends bulk finished tablets to a packaging partner, and that partner then creates blisters, adds cartons and leaflets, and applies serialisation codes, it constitutes packaging work. The defining factor is that the drug product already existed before the partner received it.
Who usually owns the bulk product
In co-packing, the product owner typically retains ownership of the bulk product, or another designated manufacturer supplies it into the packaging process. The packaging partner receives and handles it under agreed-upon controls. This keeps their role firmly on the packaging side and supports a clearly defined scope for a pharma packaging supplier.
Who supplies a finished or semi-finished product to a co-packer
The product owner, licence holder, or appointed manufacturer usually supplies the medicine to the co-packer. The key takeaway is that the medicine arrives in a ready form for packing. As a result, the external partner performs packaging operations rather than drug product production.
How component supply can be split by agreement
Packaging components can be supplied by the customer, by the packaging partner, or collaboratively by both. The commercial agreement should explicitly state who owns the components, who approves the specifications, and how inventory replenishment works. Because this split is so common, it should not be used in isolation to determine whether a project involves packaging or manufacturing.
How to assess co-packing versus contract manufacturing by process scope
The second decision point revolves around process scope. The external partner may handle primary packaging, secondary packaging, labelling, and serialisation. However, these remain strictly packaging activities as long as the drug product is supplied in bulk and the work is limited to placing it into the agreed-upon pack. Therefore, performing primary packaging does not automatically classify a partner as a manufacturer.
This represents one of the most common areas of confusion in co-packing versus contract manufacturing. Some teams mistakenly assume that the first pack to directly touch the product must fall under manufacturing. In the pharmaceutical industry, that definition is far too broad. A better test is to ask whether the external party actively formulated the medicine or merely received it ready for packing.
A practical case illustrates this difference perfectly. If a customer supplies a finished capsule and requires a validated pack for a single unit, the challenge lies entirely in pack design, tooling, and line execution. Our single capsule packaging example demonstrates how this specific packaging challenge unfolds in real life.
Primary packing can still be packaging work
Primary packing refers to the first direct pack, such as a blister or any other format that physically touches the product. This process still qualifies as co-packing when the medicine is pre-supplied and the partner merely places it into the approved packaging. Ultimately, the difference between co-packing and contract manufacturing depends on who handles the product-making step, not solely on the level of packaging involved.
Secondary packing, labelling, and serialisation
Secondary packaging includes cartons, leaflets, bundles, and shipper preparation. Labelling and serialisation also sit comfortably within the packaging scope. These steps are crucial because they support market supply, ensure traceability, and maintain patient safety, but performing them does not mean the same company manufactured the medicine.
What stays outside the packaging scope
Drug product production firmly remains outside the packaging scope. This includes formulating the medicine from raw materials or active pharmaceutical ingredients. Consequently, the packaging partner should never be described as the manufacturer unless they actively perform that specific manufacturing step.
How to assess co-packing versus contract manufacturing by release responsibility
The third critical decision point is batch release responsibility. This is often where project teams slow down, as the company performing the physical packaging work is not always the entity holding the formal release duty. In the pharmaceutical industry, that responsibility must be assigned to a specifically authorised role and documented clearly.
Marketing authorisation, which many teams refer to as the product licence, is entirely separate from packaging activity. One company may hold the licence, while another executes the packaging work under contract. Therefore, physically performing the work and holding the formal regulatory role are two distinct responsibilities.
This is why batch release responsibility needs specific attention during co-packing versus contract manufacturing reviews. A packaging partner might pack, label, and serialise the product while providing all necessary records; even so, final release responsibility does not automatically stem from the title of co-packer. The same logic applies to a manufacturer if the quality agreement assigns the final release to a different party.
Marketing authorisation is separate from packaging work
Holding a marketing authorisation does not mean the same company performs every physical task. Instead, it defines a formal product role, whereas packaging work defines a strictly operational role. Because of this, project teams should separate licence-related questions from service scope questions during the planning phase.
Batch release responsibility must be assigned
Batch release responsibility belongs solely to the authorised role named in the quality system and the written agreement. This represents one of the most important practical checks in any outsourced project, as incorrect assumptions here can trigger severe compliance risks and launch delays.
Why the term co-packer does not define legal responsibility
The term "co-packer" describes the packaging work itself; it does not dictate who releases the batch or who holds the product licence. Therefore, job titles alone are insufficient. The quality setup, the technical agreement, and the explicitly assigned roles must consistently confirm the actual responsibility model.
Co-packing versus contract manufacturing in outsourced governance
Proper governance language makes responsibilities much easier to identify. In EU GMP terminology, a "contract giver" is the company outsourcing the work, and a "contract acceptor" is the company executing it. These contract giver and contract acceptor terms apply seamlessly to both packaging and manufacturing arrangements, making them highly useful across all pharmaceutical outsourced activities.
This language works well because it maintains a clear focus on control and execution. A co-packer can act as the contract acceptor, and a contract manufacturer can also be the contract acceptor. The true difference lies in the actual work being outsourced and the specific responsibilities assigned in the written agreement.
The written agreement must comprehensively cover duties, information flows, change controls, deviation handling, audit access, and approval routes. Furthermore, it should explicitly state who supplies the bulk product, who procures the components, who approves the artwork, who manages the serialisation data, and who holds the batch release responsibility. By mapping this out, the project team can clearly see the full operational boundary well before production starts.
Contract giver and contract acceptor in EU GMP language
The contract giver remains ultimately responsible for controlling the outsourced activity, even when a third party performs the physical work. Meanwhile, the contract acceptor completes the agreed-upon tasks within their approved scope. This formal structure helps significantly reduce confusion in complex, mixed-supplier models.
What the written agreement must cover
The agreement should define all handover points in plain, unambiguous language. It needs to detail materials, documents, records, approvals, timelines, and escalation routes. This depth is vital, as a single missing handover can negatively impact line readiness, interrupt data flows, or delay the final release timing.
Information flow, change control, and audit access
Information flow matters immensely because unexpected packaging changes can alter components, line setups, and release documentation. Change control procedures must clearly show who reviews and approves these updates. Additionally, audit access should be agreed upon early, allowing the contract giver to verify that the outsourced work remains fully under control.
A simple co-packing versus contract manufacturing responsibility matrix
A packaging responsibility matrix can help project teams compare typical setups before drafting a full contract. Since real-world projects inevitably vary, every point still requires written confirmation. Nevertheless, this format helps supply chain, procurement, and project teams organise their initial discussions quickly and effectively.
• Drug product production: In a typical co-packing setup, this is handled by the product owner or a separate manufacturer. In a contract manufacturing setup, it is handled by the external manufacturer. Always confirm in the written agreement: yes.
• Bulk ownership: In a typical co-packing setup, ownership remains with the product owner or appointed manufacturer. In a contract manufacturing setup, it depends on the specific supply model. Always confirm in the written agreement: yes.
• Component sourcing: In a typical co-packing setup, this is managed by the customer, the packaging partner, or collaboratively by both. In a contract manufacturing setup, it is handled by the customer, the manufacturer, or both. Always confirm in the written agreement: yes.
• Artwork approval: In both co-packing and contract manufacturing setups, this is usually managed by the product owner. Always confirm in the written agreement: yes.
• Packaging operations: In a typical co-packing setup, the packaging partner executes this step. In a contract manufacturing setup, it may be handled by the manufacturer, a separate packer, or both. Always confirm in the written agreement: yes.
• Serialisation data: In a typical co-packing setup, this is managed by the product owner, a service provider, or the packaging partner under a specific agreement. Contract manufacturing setups share this same possible split. Always confirm in the written agreement: yes.
• Batch release: In a typical co-packing setup, this falls to the authorised assigned role and is not automatically granted to the packer. In a contract manufacturing setup, it likewise falls to the authorised assigned role rather than automatically to the manufacturer. Always confirm in the written agreement: yes.
This matrix illustrates why a single label is rarely sufficient. Bulk product ownership, operational scope, and batch release responsibility can sit with entirely different parties. Therefore, the project's parameters must be mapped out early if more than one external supplier is involved.
Where our packaging scope fits
We operate exclusively on the packaging side of the boundary, meaning we do not manufacture the drug product. That distinction is important because many projects require extensive support long before the first packaged unit ever reaches the line. Pack design, tooling readiness, and overall manufacturability often dictate whether a project will run smoothly later on.
We fully support design for manufacturability, allowing teams to align their pack concepts, component readiness, and line requirements early in the process. We also produce packaging components in-house and support a variety of specialist formats, including wallet packs, dosage schedule packs, and custom packaging for rare disease treatments.
Our capabilities include comprehensive primary and secondary packaging solutions, complete with serialisation, while remaining clearly within the packaging scope. For project teams that desire more internal control further down the line, we can also provide the necessary packaging equipment for insourcing. In this way, we support a broad and flexible packaging path without ever crossing over into drug product manufacturing.
Design for manufacturability before packing starts
The true packaging boundary often begins well before line operations commence. Early design choices significantly affect component fit, validation efforts, line efficiency, and end-user safety. Because of this, engaging in early packaging development can drastically reduce the need for later changes, helping teams make better project decisions sooner.
In-house packaging components and specialist formats
Component control matters deeply, as a poor physical fit or late supply can bring a project to a complete halt. By producing our packaging components in-house, we foster better alignment between the initial pack design and the final pack execution. This capability proves especially useful when standard formats do not adequately fit the product or its intended use case.
Primary and secondary packaging solutions, including serialisation
A single packaging partner can seamlessly support several connected packaging steps. This might include primary packing, secondary packing, labelling, and serialisation. Even so, all of that work firmly remains within the packaging scope, provided the medicine itself is supplied ready for packing.
Packaging equipment for insourcing when the customer prefers that route
Some pharmaceutical companies choose to outsource first and then insource later. In such cases, providing packaging equipment can smoothly support this transition. It grants the customer more direct control over their future packaging operations while clearly keeping drug product manufacturing completely outside our role.
Clear boundary: packaging partner, not drug product manufacturer
We design, prepare, and execute the packaging work, but we do not manufacture the actual drug product. This clear, definitive boundary helps project teams accurately decide where our role best fits within a larger supply chain.
Common questions
Is primary packaging always contract manufacturing?
No. Primary packaging can still be considered co-packing if the medicine is pre-supplied and the task is strictly limited to placing it into the agreed-upon pack. The ultimate deciding factor is always whether the external party formulates the medicine or only packages it.
What is the main difference between co-packing and contract manufacturing?
The primary difference lies in where the external party enters the production process. In co-packing, the medicine already exists and is supplied specifically for packaging. In contract manufacturing, the external party actively produces the drug product. This is the most straightforward distinction for anyone searching for the difference between contract packing and contract manufacturing.
Can a contract manufacturer and a co-packer be different companies in one project?
Yes. In fact, this is incredibly common in the pharmaceutical industry. One company might formulate the drug product, another might supply the packaging components, and a completely separate packaging partner might carry out the physical packaging and serialisation. Because of this, mixed-scope projects require distinct handover points and a carefully written responsibility map.
Who owns the packaging components?
There is no single, universal rule. The customer may supply them, the packaging partner may supply them, or both entities might split the task. The commercial agreement should explicitly state ownership, design specifications, approval processes, and replenishment rules so that no confusion arises later on.
Does the packaging partner automatically release the batch?
No. Batch release responsibility must be explicitly assigned to an authorised role. A packaging partner can perform the operational work and provide all necessary records, but release responsibility does not automatically accompany the packaging task or the title of co-packer.
How do you document the handover points?
You should use a comprehensive written agreement accompanied by a simple responsibility map. Clearly define who owns the bulk product, who sources the components, who approves the artwork, who manages the serialisation data, who performs the packaging work, and who ultimately releases the batch. Documenting this makes the boundary crystal clear before the project grows more complex.
Practical next step for project teams
If your team is still trying to decide where a new project sits, start with three basic checks: bulk product ownership, process scope, and batch release responsibility. Answering these questions often reveals quickly whether you need a manufacturer, a packaging partner, or both. It also helps prevent scope confusion long before technical work and supplier planning move forward.
If the project includes specialist packs, custom pack development, or complex tooling questions, be sure to involve packaging expertise early. This proactive approach helps immensely, as pack design, component fit, and line requirements can impact your entire timeline. If you want a simple first step, you can start our packaging quickscan to help structure the initial discussions inside your team.
Request a free sample now!
